Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014;7(2):92-96.
doi: 10.1007/s12254-014-0146-8. Epub 2014 Jun 13.

Follow-up in soft tissue sarcomas

Piotr Rutkowski  1 , Iwona Lugowska  1
Affiliations
Review

Follow-up in soft tissue sarcomas

Piotr Rutkowski et al. Memo. 2014.

Abstract

The strategy for the follow-up of soft tissue sarcomas (STS) after therapy is tailored to the individual risk of recurrence and based on efficient rather than sophisticated methods of observation. Along with advances in the treatment of sarcomas, earlier detection of a less advanced and resectable recurrent disease (local or metastasis-especially to the lungs) can prolong patient survival. Since the majority of STS relapses occur within 5 years after treatment (approximately 80 % of metastases to the lung and close to 70 % of local recurrences within the first 2-3 years), in the period between 2 and 3 years after treatment, it is mandatory to follow-up patients every 3 months and perform careful history and physical examination (especially scars after surgery of the primary site) and a chest X-ray. There is no reason to perform other studies in asymptomatic patients (unless the patient reports symptoms). In case of retroperitoneal or intraperitoneal STS (including gastrointestinal stromal tumor), contrast-enhanced computed tomography of the abdomen and pelvis is recommended as the follow-up modality of choice. In this paper we outline the current recommendations for the follow-up strategy.

Keywords: Follow-up; Gastrointestinal stromal tumors; Recurrences; Sarcoma.

PubMed Disclaimer

References

    1. Cool P, Grimer R, Rees R. Surveillance in patients with sarcoma of the extremities. Eur J Surg Oncol. 2005;31:1020–4. doi: 10.1016/j.ejso.2005.07.015. - DOI - PubMed
    1. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Soft Tissue Sarcomas, Version 1.2013.
    1. Grimer R, Judson I, Peake D, Seddon B. Guidelines for the management of soft tissue sarcomas. Sarcoma. 2010;2010:506182. - PMC - PubMed
    1. Chou YS, Liu CY, Chen WM, Chen TH, Chen PC, Wu HT, Chiou HJ, Shiau CY, Wu YC, Liu CL, Chao TC, Tzeng CH, Yen CC. Follow-up after primary treatment of soft tissue sarcoma of extremities: impact of frequency of follow-up imaging on disease-specific survival. J Surg Oncol. 2012;106(2):155–61. doi: 10.1002/jso.23060. - DOI - PubMed
    1. Ruka W, Rutkowski P, Krzakowski M, Grzesiakowska U, Ptaszyński K, Jeziorski A, Polkowski W, Ryś J, Słuszniak J, Dziewirski W, Morysiński T, Świtaj T, Bębenek M, Siedlecki JA, Limon J, Nowecki ZI. Soft tissue sarcomas in adult patients –guidelines for diagnosis and treatment. Nowotwory – Journal of Oncology. 2010;60:55–65.

LinkOut - more resources